07/09/2020
Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe Orphazyme A/S (ORPHA.CO) (the “Company”), a...
13/08/2020
F2G closes USD 60.8 Million financing to fund late stage development of novel mechanism antifungal agent F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US $60.8...
11/08/2020
Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize...
17/07/2020
Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the...
08/07/2020
VAXIMM Appoints Thomas D. Szucs, MD, as Chairman of the Board VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Thomas D. Szucs, MD, as Chairman of the Supervisory Board. He succeeds Thomas...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments